Drug Profile

LY 01620

Alternative Names: LY-01620

Latest Information Update: 27 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Luye Pharma Group
Class Antineoplastics; Cancer vaccines; Papillomavirus vaccines; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Squamous intraepithelial lesions of the cervix

Most Recent Events

31 Aug 2026 Luye Phamra plans a phase II trial of LY 01620 for squamous intraepithelial lesions of the cervix in China
24 Mar 2025 Phase-I clinical trials in Squamous intraepithelial lesions of the cervix in China (unspecified route) (Luye Pharma pipeline, March 2025 )
13 Aug 2024 Preclinical trials in Squamous intraepithelial lesions of the cervix in China (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com